Becton, Dickinson and Co. | BDX - Gross Profit On Sales


Becton, Dickinson and Co. reported $2.32B in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Abbott USD 6.65B 787M Jun/2026
Agilent USD 990M 44M Mar/2026
Align Technology USD 757.43M 20.84M Jun/2026
AngioDynamics USD 44.78M 2.93M Sep/2025
Baxter International USD 1.14B 251M Jun/2026
Becton, Dickinson and Co. USD 2.32B 161M Jun/2026
Bio-Rad Laboratories USD 309.4M 35.8M Mar/2026
Boston Scientific USD 3.82B 210M Jun/2026
Cooper Companies USD 735.4M 40.2M Mar/2026
Danaher USD 3.61B 20M Jun/2026
Dentsply International USD 493M 66M Jun/2026
Dexcom USD 750.3M 42.4M Mar/2026
Edwards Lifesciences USD 1.35B 62.6M Jun/2026
Globus Medical USD 548.17M 51.91M Jun/2026
Insulet USD 562.6M 21.8M Jun/2026
Integra LifeSciences USD 215.97M 2.77M Jun/2026
Intuitive Surgical USD 2.02B 193.4M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Medtronic USD 6.01B 595M Mar/2026
Solventum Corp USD 1.29B 189M Jun/2026
Stryker USD 4.5B 688M Jun/2026
Tandem Diabetes Care USD 144.78M 7.99M Jun/2026
Teleflex USD 331.71M 24.28M Jun/2026
Terumo JPY 178.54B 29.52B Jun/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Zimmer Biomet Holdings USD 1.36B 149.4M Jun/2026